BioGaia signs a distribution agreement with Recordati in Italy

BioGaia has entered into an exclusive distribution agreement with Recordati in Italy for BioGaia’s probiotic products.

BioGaia signed a long-term agreement establishing a direct relationship with Recordati for the exclusive distribution of probiotics in the Italian market. Recordati is a global pharmaceutical company listed on the Italian stock exchange, with over 4,450 employees and operations in multiple markets worldwide.

BioGaia already operates in partnership with Recordati in Spain and Portugal.

The agreement replaces a previous sub-license and directly grants Recordati exclusive rights to continue distributing key products from BioGaia's product portfolio under the well-established brand Reuflor. This includes BioGaia’s globally leading probiotic drops and tablets for balancing the microbiome.

Sebastian Heimfors, Vice President and Chief Commercial Officer at BioGaia says: “With Recordati as our dedicated distribution partner in Italy, we hope to further strengthen our position in Italy, one of the most important markets for probiotics in Europe.”

Follow us:
Subscribe to BioGaia press releases here
LinkedIn here

Contacts:
Alexander Kotsinas, CFO
Email: alexander.kotsinas@biogaia.com
Phone: +46 735 00 11 11

Mikaela Idermark Stern, Corporate Communications
Email: mikaela.idermark.stern@biogaia.com
Phone: +46 730 95 61 50

About BioGaia
BioGaia is an innovative Swedish healthcare company that develops, markets, and sells probiotic products with documented health benefits. The products are sold through local distribution partners or via its own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com